Author

Stephanie Beers

Observed name: S. Beers

Institution: Rutgers Cancer Institute

Observed institutions: Northwestern University, Wayne State University, Vanderbilt-Ingram Cancer Center, Rutgers Cancer Institute

ORCID: 0000-0001-6916-1177

Observed ORCID: 0000-0001-6916-1177

OpenAlex ID: A5005037573

Sequencing topotecan and etoposide plus cisplatin to overcome topoisomerase I and II resistance: a pharmacodynamically based Phase I trial.

2003 · Joseph Aisner, Rita Musanti, et al. · PubMed · 18

COVID-19 Vaccine Responses in Patients With Plasma Cell Dyscrasias After Complete Vaccination

2021 · Mansi R. Shah, Alissa Gabel, et al. · Clinical Lymphoma Myeloma & Leukemia · 13

Phase I evaluation of sequential topoisomerase targeting with irinotecan/cisplatin followed by etoposide in patients with advanced malignancy.

2003 · Edward J Licitra, Viral Vyas, et al. · PubMed · 11

Phase I dose escalation and safety study of a semi-solid matrix (SSM) formulation of oral irinotecan and capecitabine tablets in patients with advanced solid tumors

2004 · A. I. B. Benson, E. Rubin, et al. · Journal of Clinical Oncology · 6

Works count: 4

Citation count: 48

H-index: 4

I10-index: 3